{"preliminary_commentary":{"by_channel":{"x_thread":4,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"TREC","nct_id":"NCT01165112","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trec-nct01165112. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TREC","arms":[{"description":"Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60 minutes on days 1-3, and carboplatin IV over 60 minutes on day 1. Patients with CD20+ T-cell lymphoma disease also receive rituximab IV on day 2 or 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.","label":"Treatment (chemotherapy and monoclonal antibody therapy)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2015-06","type":"ACTUAL"},"conditions":["Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Hodgkin Lymphoma"],"enrollment":{"count":48,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Bendamustine Hydrochloride","otherNames":["Ribomustin","SyB L-0501","Treanda"],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Rituximab","otherNames":["MOAB IDEC-C2B8"],"type":"BIOLOGICAL"},{"name":"Etoposide","otherNames":["Lastet"],"type":"DRUG"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"}],"last_update":"2018-12-05","lead_sponsor":"University of Washington","official_title":"A Phase I/II Trial of Bendamustine/Treanda®, Rituximab, Etoposide, and Carboplatin for Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC)","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2015-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Maximally Tolerated Dose of Bendamustine Hydrochloride That Can be Combined With Rituximab, Carboplatin, and Etoposide Chemotherapy in Patients With Relapsed or Refractory Lymphoid Malignancies","timeFrame":"Up to 5 weeks after the last course"},{"measure":"Safety and Toxicity of This Regimen","timeFrame":"Up to 5 weeks after the last course"}],"references":[{"citation":"Budde LE, Wu D, Martin DB, Philip M, Shustov AR, Smith SD, Gooley TA, Chen TL, Libby EN, Chen EY, Kojouri K, Langerak A, Roden JE, Press OW, Gopal AK. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14.","pmid":"30596402","type":"DERIVED"}],"start_date":{"date":"2010-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma","url":"https://clinicaltrials.gov/study/NCT01165112"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trec-nct01165112"}